C5 and HELLP syndrome: Since the involvement of complement has been reported in multiple studies, C5 monoclonal antibody eculizumab has been tested to treat HELLP syndrome (Pierik et al. 2020; Burwick and Feinberg 2013; Brocklebank and Kavanagh 2017).